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ABSTRACT
The disease, Leishmaniasis, is caused by the protozoal parasite Leishmania,
which is transmitted by the bite of an infected Phlebotomine female sandfly. It is a
significant health problem in tropical regions of the world and new therapeutic
approaches for treating this disease are urgently needed.
Protozoal MAPKs (Mitogen Activated Protein Kinases) play important roles in
parasite viability and infectivity and as such, represent viable drug targets. It has been
demonstrated that LmxMPKl is an essential MAPK required for the parasite to establish
infection and for proliferation of the amastigote stage (the mammalian stage of the
parasite) of the parasite. In our study we focused on LmxMPKl (Leishmania mexicana
mitogen-activated protein kinase 1), which shares sequence homology to human ERK8
and p38 MAPK.
In our study we have successfully expressed LmxMPKl enzyme in HEK293T
cells and BL21-AI cells. Mammalian expressed LmxMPKl was largely inactive but
demonstrated low level basal activity as assessed by incorporation of the [y p] labeled
ATP into MBP. In this assay activity was inhibited by BIRB796. On the other hand,
bacterial expressed LmxMPKl, when assayed using an assay measuring consumption of
ATP, was active but did not phosphorylate MBP which suggests we are measuring auto
phosphorylation of the enzyme itself. Interestingly, BIRB796 did not exhibit inhibitory
activity in this assay.
In collaboration with Dr. Goodey, the direct binding of BIRB796 to active and
inactive (dephosphorylated) LmxMPKl was assessed using tryptophan fluorescence
I

quenching. Surprisingly, BIRB796 exhibited high affinity binding only to active
LmxMPKl.
My results suggest that BIRB796 binds to active LmxMPKl with high affinity,
but does not result in inhibition of the enzyme. This unusual result may indicate varying
conformational or phosphorylation states of the enzyme depending upon the source (i.e.
mammalian or bacterial) of recombinant enzyme.
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INTRODUCTION:
Leishmaniasis
Leishmaniasis is a tropical disease that affects about 350 million individuals
worldwide. The annual incidence is estimated at 1.5 - 2 million with 70 000 deaths each
year [1]. Leishmaniasis is found in parts of about 88 countries. The settings in which
leishmaniasis is found range from rain forests in Central and South America to deserts in
West Asia. More than 90 percent of the world's cases of leishmaniasis are in India,
Bangladesh, Nepal, Sudan, and Brazil [2].
Leishmaniasis occurs in three major clinical forms: cutaneous leishmaniasis (CL),
mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). CL is caused by
Leishmania major, L. tropica, L. mexicana, L. amazonensis, L. panamanesis, and L.
guyanensis. The cutaneous form of leishmaniasis produces large numbers of skin ulcers,
as many as 200 in some cases, on the exposed parts of the body. MCL is caused by L.
braziliensis [3]. It is an uncommon manifestation of cutaneous leishmaniasis that may
present years after the initial skin ulcer has healed. This metastatic complication of the
primary lesions; results in disfiguring and ulceration of mucous membranes of the nose,
mouth and throat cavites [4]. Visceral leishmaniasis is produced by L. donovani, L.
infantum or L. chagasi. It is characterized by fever, substantial weight loss,
hepatomegaly, and anaemia. It is fatal without treatment and sometimes fatal despite of
treatment [5].
Leishmania species are transmitted by a phlebotome sandfly vector [6].
Leishmania organisms have a relatively simple life cycle, characterized by two principal
stages: the flagellated mobile promastigotes living in the gut of the sandfly vector and the
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immobile amastigotes within phagolysosomal vesicles of the vertebrate host
macrophages [7, 8] (Figure 1). Infected female sandflies transmit the disease by
inoculating the promastigote form into the skin during their blood meal. In the vertebrate
host, the parasites are phagocytosed by macrophages and dendritic cells in the dermis.
After uptake and internalization of promastigotes into a phagosome, fusion with
lysosomes proceeds as normal and the parasites survive in the phagolysosome. During
this process, the promastigotes rapidly transform into amastigotes within 12-24 h and
continue to grow and divide within the phagolysosomal compartment [9]. When a sandfly
takes a blood meal from an infected vertebrate host, it ingests amastigote-containing
macrophages and monocytes. The amastigotes are released into the sandfly midgut where
they develop into flagellated promastigotes. These go through a process called
metacyclogenesis, in which the dividing, non-infective procyclic form acquires virulence
capabilities and is transformed into a non-dividing, infective metacyclic form [10]. The
metacyclic promastigotes migrate into the pharynx and buccal cavity, ready for
transmission during a next blood meal [11].
There are no effective vaccines to prevent leishmaniasis [12, 13, 14]. The
classical treatment of leishmaniasis requires the administration of poorly tolerated and
toxic drugs [14]. Limitations of current drugs, pentavalent antimonials and the polyene
antibiotic amphotericin B, include significant toxicity, high cost and long treatment
courses. Drug resistance to anti-leishmanial drugs has developed in certain parts of the
world [15]. There is a pressing need to identify new parasitic drug targets for the
development of new anti-leishmanial drugs. One emerging class of anti-parasitic drug
targets are protein kinases [16]. Protein kinases are key regulatory proteins and represent
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a drug target in Leishmania. Two leishmania mitogen- activated protein kinases (MAP
kinases) have been validated as potential drug targets through genetic means [17, 18, 19].

MAP Kinases
Mitogen-activated protein kinases (MAPKs) are evolutionary conserved enzymes
connecting cell-surface receptors to critical regulatory targets within cells [20]. MAPK
pathways regulate diverse processes ranging from proliferation and differentiation to
apoptosis. Activated by an enormous array of stimuli, they phosphorylate numerous
proteins, including transcription factors, cytoskeletal proteins, kinases and other enzymes,
and greatly influence gene expression, metabolism, cell division, cell morphology and
cell survival [21]. MAPK activity is regulated through three-tiered cascades composed of
a MAPK, MAPK kinase (MAPKK, MKK or MEK) and a MAPKK kinase or MEK
kinase (MAPKKK or MEKK) [22].
Five major MAPK subfamilies, containing a characteristic dual phosphorylation
site in the kinase activation domain have been identified in mammalian cells [23, 24, 25].
The first subfamily, ERK1 and ERK2 (extracellular signal-regulated kinases), possess a
TEY dual phosphorylation motif. [26]. ERK1 and ERK2 regulate proliferation,
differentiation and meiosis, and learning and memory in the brain. They are activated by
mitogenic stimuli such as growth factors, cytokines and phorbol esters, which activate a
variety of receptors and G proteins [21]. A second subfamily is represented by the p38
stress response MAPKs (p38a, p38/?, p38y, and p38e)) which contain a TGY
phosphorylation motif. p38MAP kinases play an important role in asthma and
autoimmunity in humans and are activated by numerous physical and chemical stresses,
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including hormones, UV irradiation, ischemia, cytokines including interleukin-1 and
tumor necrosis factor, osmotic shock and heat shock [21, 27].
A third subfamily, the c-Jun-activated kinases (JNK1, JNK2, and JNK3), contain
a TPY activation motif and play crucial roles in regulating responses to various stresses,
and in neural development, inflammation, and apoptosis [28]. They too are activated by
radiation and other environmental stresses and by growth factors [21].
Two additional subfamilies are represented by ERK5 (TEY motif) and ERK8
(TEY motif). ERK5 possesses a long carboxy-terminal extension consisting of a
transactivation domain and a nuclear localization signal facilitating translocation into the
nucleus upon activation [24, 29, 30]. Recently discovered human ERK8 represents a
prototypical member of a large atypical MAPK subfamily [25]. Although these large
atypical MAPKs contain a TEY motif capable of dual phosphorylation, activation of
mammalian ERK8, is not under the control of any known MKK family member. Instead,
they are activated by auto-phosphorylation of their activation loops in response to
conformational changes in their carboxy-terminal extensions [31].

MAPK Inhibitors
A number of MAPK inhibitors have been synthesized for potential therapeutic use
in humans [32]. Type 1, kinase inhibitors bind exclusively within the ATP (adenosine
triphosphate) binding site of the active DFG-in kinase conformation in which the
activation loop is open and extended such that ATP and substrate molecules can bind
(Figure 2 & 3). Type II inhibitors bind partially within the ATP binding site while also
extending into an allosteric binding pocket and stabilize the inactive kinase conformation.

4

Type III inhibitors also stabilize the DFG- out conformation but bind exclusively within
the allosteric pocket [32]. The structural transition associated with the binding of both
type II and III inhibitors increases the drug-target residence time and increases efficacy at
lower drug concentrations [33]. Non-phosphorylated (inactive) kinase binds ATP with
lower affinity resulting in less competition for the small molecule inhibitor [34, 35].
Thus, selectivity and efficacy of the inactive form of the enzyme has been found more
attractive as target for drug design [34].
A novel allosteric binding site has been reported for a diaryl urea class of highly
potent and selective inhibitors against human p38 MAP kinase (Figure 4) [36]. The
formation of this binding site requires a large conformational change not observed
previously for any of the protein Ser/Thr kinases. This change is in the highly conserved
DFG motif within the active site of the kinase. Solution studies demonstrate that the
compound, BIRB796 (Figure 5), the most potent compound in this class, has slow
binding kinetics, consistent with the requirement for conformational change [36].
Protozoan MAPKs share many common structural features with mammalian
MAPKs [19, 37], but are divergent enough that it should be possible to design drugs
preferentially targeting protozoan MAPKs [23]. My thesis research involves the study of
a Leishmania mexicana MAPK, LmxMPKl, that has been shown by deletion analysis to
be essential for the survival of amastigotes in the infected mammalian host [38]. As such,
this kinase represents a functionally validated drug target.
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Goals of Study
The goal of our research is expression and characterization of recombinant active
LmxMPKl kinase. I plan to provide confirmation of previous observations that BIRB796
exhibits inhibitory activity on LmxMPKl.

MATERIALS AND METHODS:
Generation of pDESTl 5 Gateway ® expression vector
The GST tagged LmxMPKl gene was transferred into Gateway® pDEST vectors
using in vitro recombination reaction. pDONR 221 vector consisting of LmxMPKl gene
was used as entry clone and pDEST 15 bacterial expression vector (producing N-terminal
GST tagged enzyme) as the destination vector. pDEST 15 vector was obtained as super
coiled plasmids from Invitrogen life technologies. In a 1.5 ml microcentrifuge tube,
2 ng/pl entry clone and 150 ng/pl destination vector was mixed in a total amount of 16 pi
TE reaction buffer

(10 mM tris HC1, pH 8.0, 1 mM EDTA) on ice. LR Clonase™

enzyme mix (4 pi) (Invitrogen) was added to the sample and mixed by vortexing twice
(2 sec each time). Reaction was incubated at 25°C for 3 h. After incubation, 2 pi of the
Proteinase K solution was added to the reaction and incubated for 10 min at 37°C. Same
procedure was applied for negative control except the LR Clonase™ enzyme mix was
omitted.
The recombination reactions were transformed into BL21-AI™ One Shot® cells
(Invitrogen). DNA (1 pi, prepared by recombination reaction); was added in one vial of
BL21-AI™ One Shot® cells and mixed by tapping gently. The cells incubated on ice for
30 min and heat shocked by incubating for 30 sec in the 42°C water bath. After 30 sec,
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the vial was removed and quickly placed on ice. Then, 250 pi of SOC medium was added
to the vial. The vial was placed horizontally in a 37°C shaking incubator and incubated
for 1 hour at 225 rpm. In order to select for the expression clones, 50 pi transformed cells
were plated onto a pre-warmed LB plate containing 100 pg/ml carbenicillin. The plate
was incubated at 37°C overnight.
Expression of LmxMPKl
The following day, 1 well isolated colony was innoculated in a 15 ml LB Broth
(Invitrogen) containing 100 pg/ml carbenicillin overnight. The starting culture was grown
in a 37°C incubator with aeration shaking until O.D 6oo of culture reached 0.8. Then
starting culture was transferred into 150 ml LB Broth containing 100 pg/ml carbenicillin,
o

with 1:20 dilution. The 150 ml culture was grown in 37 C shaker incubator until O.D 6oo
reached 0.6. Then the culture was induced with final concentration of 0.2% L-arabinose
for 5 h. Bacterial cells were pelleted by centrifugation at 5000 x g for 10 min and the
pellet was stored at -30 C freezer overnight.
Cells were lysed using 4 ml B-PER bacterial protein extraction reagent for 1 g of
cell pellet (Thermo Scientific) containing 1TOO Halt protease inhibitor single use EDTA
free cocktail (Pierce). The suspension was incubated for 10 min in the room temperature
and centrifuged at 15,000 x g for 5 min and the supernatant was transferred into a tube for
protein purification.
Purification of GST-tagged LmxMPKl
Purification of GST-tagged LmxMPKl was performed using high affinity GST
column resin (GenScript) as per manufacturer’s instructions [40]. Cell lysate was
7

incubated for 1 h with 0.5 ml high affinity GST column resin to allow protein binding to
the column. The column was washed with 2 ml of IX PBS four times. The column was
then washed once with 2 ml of elution buffer, containing: 25 mM HEPES, 150 mM NaCl,
1 mM DTT, 10% glycerol, 0.1 mM EDTA, and 1:100 Halts protease inhibitor (ThermoScientific). The protein was eluted with elution buffer containing 10 mM reduced
L-glutathione. Five bed volumes of elution buffer were used with 10 min incubation
during each elution.
Bradford Protein Assay
Protein concentration was determined by Bradford protein assay (Sigma-Aldrich).
Standard reference protein Bovine serum albumin (BSA) was made up as 1 mg/ml in
IX PBS (Phosphate buffer saline). The assay was performed in a half volume 96-well
plate by adding equal volumes of the samples and Bradford reagent. Total assay volume
was 80 pi and absorbance was measured at 595 nm with Synergy 2 microplate reader.
SDS-PAGE and Western blotting of GST- LmxMPKl
Protein fractions were analyzed by SDS-PAGE (Sodium Dodecyl Sulfate
Polyacrylamide Gel Electrophoresis), using X Cell Sure Lock Mini cell blotting module
(Invitrogen). Samples were prepared in NuPAGE SDS sample buffer with DTT
(Dithiothreitol) and heated at 95°C for 5 min. Samples (20 pi) were loaded on a 10-well
NuPAGE 12% Bis-Tris 1.0 mm gel (Invitrogen) and were run at 200 V for 40 min using
MOPS SDS running buffer (Invitrogen). Novex sharp pre-stained protein standards
(Invitrogen) were used on the gel as molecular weight markers (10 pi). The gel was
stained for 1 h with staining solution (0.05% Coomassie Blue, 10% acetic Acid and 44%
8

Methanol), fixed in 50% methanol and 10% acetic acid for 30 min and left for destaining
in 5% acetic acid overnight.
For Western Blotting, proteins were electro-transferred from SDS-PAGE on to
PVDF (polyvinylidene fluoride) membrane. PVDF membrane was soaked in methanol
for 30 sec, and placed in NuPAGE® Transfer Buffer (Invitrogen) containing 10%
methanol and 0.25% SDS. The electro-transfer was conducted using a TE77XP SemiDryBlotter (Hoefer Holliston, MA) for 1 h at 54 mA per blot. The membranes were then
incubated in blocking solution (5% non-fat dry milk) for 1 h, and incubated in primary
antibody for 1 h. The primary antibody was prepared in 10 mL of TBS-T (Tris buffered
saline with Tween 20) with goat Anti-GST antibody (1:1000 dilution) by GE-Healthcare,
10 mg of BSA, and 0.01% NaN3. The membrane was washed 3 times with TBST with
5 min incubations. After washing, the membrane was incubated with alkaline
phosphatase (AP) linked mouse anti-goat secondary antibody IgG (1:5000 in 10 ml of
TBST, Santa Cruz Biotechnology) for 1 h. The membrane was washed 2 times with
TBST and 1 time with distilled water, 5 min for each incubations. The western blot was
developed with 2 ml of Western Blue® Stabilized Substrate for AP (Promega) and
analyzed.
LmxMPKl Kinase Activity Determination
ADP-Glo™ Kinase Assay (by Promega) was used to measure the activity of
LmxMPKl. This assay is a luminescent ADP detection assay that provides a highthroughput screening method to measure kinase activity by quantifying the amount of
ADP produced during a kinase reaction. The assay was performed in a 96-well half
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volume plate, according to the manufacturer’s instructions [41]. Total assay volume was
set to 10 pi and Myelin Basic Protein (Invitrogen) was used as substrate. The buffer for
the assay was IX Kinase buffer A, composed of 40 mM Tris (pH 7.5), 20 mM MgCfz,
and 0.1 mg/ml BSA. After the reaction was completed, luminescence was measured
Synergy 2 microplate reader.
In order to do inhibition studies with LmxMPKl with BIRB796, the ADP-Glo™
Kinase Assay was performed as outlined earlier with the following changes: 200 ng/well
of LmxMPKl and 50 pg/mL of MBP were used. The assay concentration of BIRB796
was 1 pM or 10 pM. The positive control used was p38MAPK.

RESULTS:
LmxMPKl, was successfully expressed in bacterial cells. Using Gateway
pDONR221 vector containing the synthetic LmxMPKl gene, we generated a pDEST15
bacterial expression vector which is designed to express GST-tagged LmxMPKl as an
N-terminal epitope tagged protein (methods). In previous studies, LmxMPKl was
expressed in HEK293T cells [42]. LmxMPKl expressed in HEK293T cells exhibited
much less activity compared to mammalian expressed p38MAPK in the in vitro kinase
activity [42].
LmxMPKl was next expressed in bacterial BL21-AI™ One Shot® cells and
purified using glutathione-immobilized beads (methods). The amount of protein obtained
from the bacterial expressed GST-tagged LmxMPKl fractions were measured with
Bradford assay (Table 1). BSA (bovine serum albumin) was used as the standard for the
10

assays and standard curve generated (Figure 6). SDS-PAGE and Western blotting
analysis of various fractions from the purification procedure revealed expression of GSTtagged LmxMPKl (Figure 7) and purification of LmxMPKl from the glutathione affinity
resin. A molecular weight of 67 kDa was obtained for GST-LmxMPKl which agreed
with the predicted molecular weight of LmxMPKl of 41 kDa combined with the GST
epitope molecular weight of 26 kDa.
I next determined the catalytic activity of purified recombinant LmxMPKl
enzyme using the ADP-Glo™ Kinase Assay (Promega) in vitro kinase assay which
measures to production of ADP generated from ATP during the phosphorylation reaction.
Interestingly, unlike previous observations LmxMPKl from HEK293T cells [42],
bacterially expressed LmxMPKl appeared to be constitutively active, exhibiting
significant activity in the assay (Figure 8). However, the enzymatic activity observed was
independent of MBP suggesting it was due to auto-phosphorylation of LmxMPKl
(Figure 8). This constitutive activity of bacterially expressed LmxMPKl is similar to
observations made on human ERK8, which is distantly related to LmxMPKl [39]. ERK8
produced in mammalian HEK293T cells was largely inactive while bacterially expressed
ERK8 exhibited constitutive activity [39]. HEK293T cell expressed ERK8 was rapidly
dephosphorylated by cellular phosphatases whereas, dephosphorylation did not occur
with bacterially expressed ERK8 [39].
Previously, it was found using HEK293T expressed LmxMPKl that the low basal
activity with MPB as well as auto-kinase activity was inhibited by the p38 MAP kinase
inhibitor BIRB796 [42]. Using the constitutively active, bacterially expressed
LmxMPKl, we assayed BIRB796 at 1 pM and 10 pM for inhibition of auto-kinase
11

activity in the ADP-Glo™ Kinase Assay (methods). Suprisingly, BIRB796 did not show
inhibition of LmxMPKl auto-kinase activity at any of the concentrations assayed (data
not shown).
In order to attempt to resolve this discrepancy, we collaborated with Dr. Goodey
and her students in order to assess by direct binding studies whether or not BIRB796
interacts with bacterial expressed LmxMPKl. Direct binding of BIRB796 to active and
inactive forms of LmxMPKl was assayed using fluorescence quenching which is a
measure in the change in tryptophan fluorescence upon drug binding and resulting
conformational changes. These binding studies demonstrated that BIRB796 exhibits high
affinity (31.4 nM) binding to active LmxMPKl (Figure 9). Addition of a cell-free
HEK293T extract, as a source of protein phosphatases, to dephosphorylate bacterial
expressed LmxMPKl, resulted in a 40-fold decrease in the binding affinity (Kd = 1364).
This result indicates that BIRB796 appears to bind with high affinity to the active (autophosphorylated form) of LmxMPKl without inhibiting auto kinase activity in the in vitro
ADP-Glo™ Kinase Assay.

DISCUSSION:
LmxMPKl is a Leishmania MAP kinase essential for the survival of amastigotes
in the infected host. ERK8, is the closest mammalian ortholog of LmxMPKl displaying
43% identical amino acids in its kinase domain [18]. There is also a 35% sequence
identity with p38MAPK and LmxMPKl (Figure 10 and Figure 11). The higher influence
of threonine phosphorylation on the activity of a MAP kinase has also been found in
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ERK8 [39]. Déphosphorylation of the tyrosine residue in the TXY motif of ERK8
produced in Escherichia coli resulted in 15-20% decrease in activity compared with the
doubly-phosphorylated protein whereas the dephosphorylation of the threonine residue
using a specific phosphatase led to a decrease of 95% [18].
In this study, we focused on obtaining recombinant active LmxMPKl enzyme.
Previous attempts to obtain active LmxMPKl were unsuccessful. GST-LmxMPKl
enzyme was expressed in mammalian HEK293T cells, but exhibited minimal basal
activity [42]. Interestingly, we found in this study that bacterially expressed LmxMPKl
exhibited high levels of auto-phosphorylation as measured in the ADP-Glo™ Kinase
Assay, although we were unable to demonstrate phosphorylation of an exogenous
substrate MBP. This observation conflicts with earlier observations of both
auto-phosphorylation and phosphorylation of MBP with largely inactive HEK293T cell
expressed LmxMPKl. Attempts to inhibit LmxMPKl auto-phosphorylation with the
p38MAP kinase inhibitor, BIRB796, were unsuccessful. BIRB796 is a Type II
p38MAPK inhibitor which binds to an allosteric site within p38 which is made accessible
by an activation-loop rearrangement that is characteristic of kinases in an inactive
conformation [42]. A similar site is found in LmxMPKl, hence the rationale for testing
BIRB796 for inhibitory activity.
One hypothesis we proposed to explain the discrepancy in inhibition of
LmxMPKl derived from mammalian versus bacterial cells was that, as is the case for
p38MAPK, BIRB796 may only bind to the inactive conformation of LmxMPKl.
Bacterially expressed LmxMPKl appears to be constitutively active and therefore in the
active conformation.
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In order to assess binding directly, we collaborated with Dr. Goodey and her
students and performed fluorescence quenching studies to assess binding. We assessed
binding of BIRB796 to active, bacterial expressed LmxMPKl and LmxMPKl treated
with a HEK293T cell lysate as a source of phosphatases to dephosphorylate active
LmxMPKl. We observed that BIRB796 exhibits high affinity binding only to active
LmxMPKl. These results paint an unusual picture in which the BIRB inhibitor binds to
active LmxMPKl with high affinity, yet does not impact its auto-kinase activity. Clearly,
further evaluation is needed to clarify LmxMPKl substrate requirements and auto-kinase
activity with 32P-labeled ATP.
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FIGURES AND TABLES:

Bursting

Figure 1: Life cycle of Leishmania. Infected female sandflies inoculate promastigotes
into the skin during their blood meal. In the vertebrate host, promastigotes are
phagocytosed by macrophages, transform into amastigotes within 12-24 h, and continue
to grow and divide within the phagolysosomal compartment. When the sandfly takes a
blood meal from an infected vertebrate host, it ingests amastigote-containing
macrophages and monocytes. Procyclic noninfective promastigotes multiply in the gut
and differentiate into infective metacyclic promastigotes that migrate into the pharynx
and buccal cavity. At the next blood meal, the infective metacyclic promastigotes are
injected into the vertebrate host [2].
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Figure 2: Active site of p38MAPK. Cartoon representation of p38MAPK structure
created using PyMol. ATP is shown in yellow spheres. Superimposed active site domains
represented in stick format. DFG-in (pdb code: 1P38) active conformation is in blue,
DFG-out (pdb code: 1KV2) inactive conformation is in cyan.

Figure 3: DFG-in and DFG-out conformations of p38MAPK. Cartoon representation
of superimposed p38MAPK, DFG-in (pdb code: 1P38) active conformation is in blue,
DFG-out (pdb code: 1KV2) inactive conformation is in cyan. ATP, shown in yellow, is in
sticks format. Figure created using PyMol. DFG-out conformation closes the activation loop
and prevents ATP from binding.
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Figure 4: Binding mode of BIRB796 to p38MAPK. p38MAPK pdb code: 1KV2.
BIRB796 is represented in green, active site residues are in purple and ATP is shown in
yellow stick format. Figure created using PyMol. BIRB796, a type II MAPK inhibitor,
bind partially within the ATP binding site while also extending into an allosteric binding
pocket and stabilize the inactive kinase conformation.

Figure 5: Structure of p38 inhibitor, BIRB796. Structure of diaryl urea based p38MAP
kinase inhibitor, BIRB796. Molecular Weight: 527.7 g/mol Molecular Formula:
C31H37N5O3. IUPACName: l-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3 yl]-3-[4-(2morpholin-4-ylethoxy)naphthalen-1-yl]urea
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Standard Curve for Bradford Assay

Figure 6: Standard curve for Bradford assay. Bovine serum albumin (BSA) was used
as standard reference protein.

Sa m p le

LmxMPKl
(expressed in
BL21-AI cells)

Crude Extract
(pg/mL)

Flow Through
(pg/mL)

Washes
(pg/mL)

(Pg/mL)

2720

4634

2034

175

Eluents

Table 1: Bradford Assay Protein Concentrations. Protein concentrations of GST
tagged LmxMPKl expressed in BL21-AI cells measured by Bradford Assay.
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Figure 7: Purification of bacterial expressed GST-LmxMPKl. Molecular weight
markers (lane 1), Positive Control - purified GST (lane 2), Negative Control - BL21-AI
cell extract (lane 3), GST-LmxMPKl - Crude Extract (lane 4), GST-LmxMPKl - Flow
through (lane 5), GST-LmxMPKl - Wash-1 (lane 6), GST-LmxMPKl - Wash-5 (lane
7), GST-LmxMPKl - Eluent-1 (lane 8), GST-LmxMPKl - Eluent-2 (lane 9), and GSTLmxMPKl - Eluent-3 (lane 10). (A) Comassine brilliant blue stained SDS - PAGE gel,
4-12% Bis-Tris gel. (B) Western blot of GST-LmxMPKl developed using goat anti-GST
polyclonal IgG antibody.
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Enzyme Dilution

(A)

(B)

Figure 8: Activity of LmxMPKl, ADP-Glo Kinase Assay. (A) ATP to ADP
conversion. The total concentration of nucleotide (ATP + ADP) in the reaction was 10
pM. (B) Graph is showing the change in enzyme activity without substrate. Assayed
enzyme concentrations was 100 ng/well, 200 ng/well, 400 ng/well and 800 ng/well.
Bacterial expressed GST-LmxMPKl activity demonstrated linear increase with the
increasing enzyme concentration. (C) Graph is displaying the change in GST-LmxMPKl
activity by substrate concentration for different enzyme concentrations. 0-0.250 mg/ml
of MBP concentration was covered in the assay.
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LnuMPKi with HEK296T Cell Lysate

HEK293T cells with BIRB796

BIRB796 (nM)

(A)

(B)

LmxMPKl (10 sec)

LmxMPKl (15 sec)
G

BERB796(nM )

(C)

7 10 '

BIR B796 (nM)

(D)

Figure 9: BIRB796 Binding to LmxMPKl. BIRB796 binding to bacterial expressed
LmxMPKl was measured with fluorescent quenching (290 nm excitation and 340 nm
emission wavelength). Fluorescence intensity vs. BIRB796 concentration graphs plotted.
(A) Negative control. The experiment was run with 1 ml of 1.16 mg/mL HEK293T cell
lysate without LmxMPKl. (B) The experiment was run with 100 nM LmxMPKl and
HEK293T cell lysate. The Kd calculated as 1364 nM. (C) The experiment was run with
100 nM LmxMPKl. Fluorescent intensity was measured after 10 sec. Kd calculated as
31.4 nM. (D) The experiment was run with 100 nM LmxMPKl. Fluorescent intensity
was measured after 15 sec. Kd calculated as 112.0 nM.
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Figure 10: Sequence alignment of ERK8, LmxMPKl, and p38MAPK. ClustalW2
sequence alignment of ERK8 (uniprot code: Q8T08), p38a MAPK (pdb code: 1KV2) and
LmxMPKl (uniprot code: 000872). Active site residues and phosphorylation lip
highlighted in cyan.
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sp I08TD08|MK15_HUMAN
tr1000872|000872_LEIME

Figure 11: Phylogram of ERK8 and LmxMPKl. ERK8 uniprot code: Q8T08,
LmxMPKl uniprot code: 000872. Figure created with ClustalW2. Figure is showing that
ERK8 and LmxMPKl are evolutionaryly similar and ERK8 is the closest kinase to
LmxMPK 1 in the human genome.

REFERENCES:
1. Reithinger, R.; Dujardin, J. C.; Louzir, H.; Pirmez, C.; Alexander, B.; Brooker, S.
Cutaneous leishmaniasis. Lancet Infect. Dis., 2007, 7, 96-581.
2. Van Assche, T.; Deschacht, M.; Inocencio da Luz, R. A.; Maes, L.; Cos, P.
Leishmania-macrophage interactions: Insights into the redox biology. Free
Radical Biology & Medicine. 2011, 51, 35-337.
3. Patel, J.A.; Shah, K.A. Leishmaniasis: A Review. Pharmacologyonline. 2008,
2:1 11.

4. Zijlstra, E.E.; El-Hassan, A. Leishmaniasis in Sudan-Visceral leishmaniasis.
Trans Roy Soc Trop Med Hyg 2001; 95(1) S1/27-S1/158
5. Johner, A.; Kunz. S.; Linder, M.; Shakur, Y.; Seebeck, T. Cyclic nucleotide
specific phosphodiesterases of Leishmania major. BMC Microbiology 2006; 6:
25.
6. Sharma, U.; Singh, S. Insect vectors of Leishmania: distribution, physiology and
their control. J. Vector Borne Dis. 2008, 45, 255-272.
7. Magill, A.; Strickland, G., Ed. Hunter's Tropical Medicine and Emerging
Infectious Diseases', Saunders: Philadelphia, 2000; pp 665-688.

23

8. Dedet, J. P.; Pratlong, F. Protozoa infection. In: Cook, G., Zumla, A. (Eds.),
Manson's Tropical Diseases. Saunders, Philadelphia,pp. 2009, 1341-1367.
9. Babior, B. M.; Kipnes, R. S.; Cumutte, J. T. Biological defense mechanisms: the
production by leukocytes of superoxide, a potential bactericidal agent. J. Clin.
Invest. 1973, 52, 741-744.
10. Da Silva, R.; Sacks, D. L. Metacyclogenesis is a major determinant of
Leishmania promastigote virulence and attenuation. Infect. Immun. 1987, 55,
2802-2806.
11. Cunningham, A. C. Parasitic adaptive mechanisms in infection by leishmania.
Exp. Mol. Pathol. 2002, 72, 132-141.
12. Herwaldt, B.L. Leishmaniasis. Lancet. 1999, 2, 1191-1199.
13. Carrio'n J.; Folgueira C.; Alonso, C. Development of immunization strategies
against leishmaniosis based on the Leishmania histones pathoantigens. Procedia
Vaccinology. 2009,1, 101-103.
14. Tiuman, T. S.; Santos, A. O.; Ueda-Nakamura, T; Dias Filho, B.P.; Nakamura,
C.V. Recent advances in leishmaniasis treatment. International Journal o f
Infectious Diseases. 2011, 15, e525-e532.
15. Sundar, S.; More, D.K.; Singh, M.K.; Singh, V.P.; Sharma, S.; Makharia, A.;
Kumar, P.C.K.; Murray, H.W. Failure of Pentavalent Antimony in Visceral
Leishmaniasis in India: Report from the Center of the Indian Epidemic. Clinical
Infectious Diseases. 2000, 31, 1104-1107.

24

16. Liotta, F.; Siekierka, J.J. Apicomplexa, trypanosoma and parasitic nematode
protein kinases as antiparasitic therapeutic targets. Curr Opin Investig Drugs.
2010,7/, 147-56.
17. Seifert, K. Structures, Targets and Recent Approaches in Anti-Leishmanial Drug
Discovery and Development. The Open Medicinal Chemistry Journal. 2011, 5,
31-39.
18. Wiese, M. Leishmania MAP kinases-familiar proteins in an unusual context. Int.
J. Parasitol. 2007, 37, 1053-62.
19. Naula, C.; Parsons, M.; Mottram, J. C. Protein kinases as drug targets in
trypanosomes and Leishmania. Biochim. Biophys. Acta. 2005,1754, 151-9.
20. Chang, L.; Karin, M. Mammalian MAP kinase signalling cascades. Nature. 2001,
410, 37-40.
21. Qi, M.; Elion, E.A. MAP kinase pathways. Journal o f Cell Science. 2005,118,
3569-3572.
22. English, J. et al. New insights into the control of MAP kinase pathways. Exp.
Cell Res. 1999, 253, 255-270.
23. Brumlik, M. J,; Pandeswara, S.; Ludwig, S. M.; Murthy, K.; Curiel, T. J. Parasite
Mitogen-Activated Protein Kinases as Drug Discovery Targets to Treat Human
Protozoan Pathogens. Journal o f Signal Transduction. 2011, volume 2011,
doilO.l 155/2011/971968.
24. Coulombe, P.; Meloche, S. “Atypical mitogen-activated protein kinases:
structure, regulation and functions,” Biochimica et Biophysica Acta. 2007,1773,
1376-1387.

25

25. Abe, M. K.; Saelzler, M. P.; Espinosa 1.1.1. R. et al. “ERK8, a new member of
the mitogen-activated protein kinase family,” Journal o f Biological Chemistry.
2002,277, 16733- 16743.
26. Yoon, S.; Seger, R. “The extracellular signal-regulated kinase:multiple substrates
regulate diverse cellular functions,” Growth Factors. 2006, 24, 21-44.
27. Whitmarsh, A. J. “A central role for p38 MAPK in the early transcriptional
response to stress,” BMC Biology. 2010, 8:47 doi: 10.1186/1741-7007-8-47
28. Kyriakis, J. M.; Banerjee, P.; Nikolakaki, E. et al.,“The stressactivated protein
kinase subfamily of c-jun kinases,” Nature. 1994, 369, 156-160.
29. Zhou, G.; Qin Bao, Z.; Dixon, J. E. “Components of a new human protein kinase
signal transduction pathway,” Journal o f Biological Chemistry. 1995, 270,
12665- 12669.
30. Lee, J. D.; Ulevitch, R. J.; Han, J. “Primary structure of BMK1: a new
mammalian MAP kinase,” Biochemical and Biophysical Research
Communications. 1995, 213, 715- 724.
31. Abe, M. K.; Kahle, K. T.; Saelzler, M. P.; Orth, K.; Dixon, J. E.; Rosner, M. R.
“ERK7 is an autoactivated member of the MAPK family,” Journal o f Biological
Chemistry. 2001, 276, 21272-21279.
32. Simard, J. R.; Grutter, C.; Pawar, V. et. al. High- Throughput Screening to
identify inhibitors which stabilize inactive kinase conformations in p38 a. . J.
Am. Chem. Soc. 2009,131, 18478-18488.

26

33. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug-target residence time and
its implications for lead optimization. Nature Review Drug Discovery. 2006, 5,
730-739.
34. Munoz, L.; Selig, R.; Yeung, Y. T.; Peifer, C.; Hauser, D.; Laufer, S.
Fluorescence polarization binding assay to develop inhibitors of inactive p38a
mitogen-activated protein kinase. Analytical Biochemistry. 2010, 401, 125-133.
35. Frantz, B.; Klatt, T.; Pang, M.; Parsons, J.; Rolando, A.; Williams, H.; Tocci,
M.J.; O’Keefe, S.J.; O’Neill, E.A. The activation state of p38 mitogen-activated
protein kinase determines the efficiency of ATP competition for
pyridinylimidazole inhibitor binding. Biochemistry. 1998, 37, 13846-13853.
36. Pargellis, C.; Tong, L.; Churchill, L. et al. Inhibition of p38 MAP kinase by
utilizing a novel allosteric binding site. Nature structural biology. 2009, 9, 268272.
37. Lacey, M. R.; Brumlik, M. J.; Yenni, R. E.; Burow, M. E.; Curiel T. J.
“Toxoplasma gondii expresses twomitogen-activated protein kinase genes that
represent distinct protozoan subfamilies,” Journal o f Molecular Evolution. 2007,
64, 4-14.
38. Wiese, M. “A mitogen-activated protein (MAP) kinase homologue of Leishmania
mexicana is essential for parasite survival in the infected host,” The EMBO
Journal. 1998,17, 2619-2628.
39. Klevemic, I.V.; Stafford, M.J.; Morrice, N.; Peggie, M.; Morton, S.; Cohen, P.
Characterization of the reversible phosphorylation and activation of ERK8.
Biochem. J., 2006, 394, 365-373.

27

40. High-Affinity GST Resin.
http://www.genscript.com/site2/document/1289 20051202165130.PDF.
(accessed March 1, 2012).
41. ADP-Glo™ Kinase Assay
http://www.promega.com/resources/protocols/technical-manuals/0/adp-glokinase-assay-protocol/ (accessed March 1, 2012)
42. Sankabathula, S. Purification and Characterization of a Leishmania Mitogen
Activated Protein Kinase: A Potentially New Anti-Parasitic Drug Target. M.S.
Thesis, Montclair State University, NJ, 2009.
43. Liu, Y.; Gray, N.S. Rational design of inhibitors that bind to inactive kinase
conformations. Nature Chemical Biology, 2006,2, Doi: 10.1038/Nchembio799.

28

